Cerus Corporation (CERS) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights a 12% YoY revenue growth and improved gross margins, indicating strong financial performance. The positive adjusted EBITDA and reduced net loss further support a positive outlook. However, the lack of discussion on risks and returns is a concern, but the strategic initiatives and optimistic guidance for 2026, including a significant partnership with BCA, suggest potential for future growth. These factors, coupled with the absence of negative guidance, lead to a positive sentiment prediction.
Key Financial Performance
Revenue Cerus Corporation reported revenue of $45.2 million for Q1 2026, representing a 12% increase year-over-year. The growth was attributed to higher demand for the INTERCEPT Blood System and expanded adoption in key markets.
Gross Margin The gross margin for Q1 2026 was 55%, up from 52% in Q1 2025. The improvement was driven by operational efficiencies and cost reductions in manufacturing.
R&D Expenses Research and development expenses were $12.8 million, a 5% increase compared to Q1 2025. The rise was due to increased investment in pipeline programs and clinical trials.
Net Loss The net loss for Q1 2026 was $8.5 million, compared to $10.2 million in Q1 2025. The reduction in net loss was primarily due to higher revenue and improved gross margins.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
2026 Product Revenue Guidance: The company provided guidance on product revenue for 2026.
Product Gross Margin Expectations: The company shared expectations for product gross margin in 2026.
Non-GAAP Adjusted EBITDA Performance: The company discussed expectations for non-GAAP adjusted EBITDA performance in 2026.
P&L Leverage: The company outlined expectations for profit and loss leverage in 2026.
Government Reimbursed R&D Expenses: The company provided expectations for government reimbursed R&D expenses in 2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
BTIG LLC
Bonello Craig
CEO Chairman
CFO Greenman
Cerus Conference
Chairman Jennings
Conference Instructions
Cowen Research
Division Bonello
Division Massaro
Division PM
EDT day
Green VP
Greenman President
Head Investor
Instructions today
Investor Relation
Jayaraman Chief
Kevin Green
LLC Research
Lee Head
Officer Kevin
PL leverage
PM EDT
President CEO
Relation Vivek
Relations Examples
Research Division
Timothy Lee
Vivek Jayaraman
conference Head
conference pleasure
day Cerus
pleasure conference
CERS Transcript
Cerus Corporation (CERS) Q1 2026 Earnings Call Transcript
Positive5-1
The earnings call highlights a 12% YoY revenue growth and improved gross margins, indicating strong financial performance. The positive adjusted EBITDA and reduced net loss further support a positive outlook. However, the lack of discussion on risks and returns is a concern, but the strategic initiatives and optimistic guidance for 2026, including a significant partnership with BCA, suggest potential for future growth. These factors, coupled with the absence of negative guidance, lead to a positive sentiment prediction.
Cerus Corporation (CERS) Q4 2025 Earnings Call Transcript
Positive3-2
The earnings call summary shows strong financial performance with a 16% revenue increase and positive EBITDA. The company raised guidance and anticipates record Q4 2025 revenue. Despite margin pressures, growth in EMEA and North America, and strong product demand, particularly in the IFC segment, are positive signals. The Q&A reveals optimism about market penetration and future cash flows. While there are concerns about production costs and the BARDA contract expiration, the overall sentiment is positive, suggesting a 2% to 8% stock price increase over the next two weeks.
Cerus Corporation (CERS) Q3 2025 Earnings Call Transcript
Unknown11-6
The earnings call presents a mixed picture. Positive factors include a raised revenue guidance, strong IFC sales growth, and a shift to a kit-based sales model that may improve margins. However, negative aspects such as delays in CE Mark approval, inflationary pressures, and foreign exchange volatility pose risks. The Q&A reveals confidence in supply capabilities and cost control measures, but external factors impacting margins remain. Given these mixed signals and the absence of a market cap, a neutral outlook is appropriate.
Cerus Corporation (CERS) Q2 2025 Earnings Call Transcript
Positive8-5
The earnings call reveals strong financial performance with significant revenue growth across regions and stable gross margins. The company maintains positive operating cash flow and adjusted EBITDA. Despite some risks like FX rates and regulatory shifts, management's clear responses in the Q&A and optimistic guidance, particularly in revenue and IFC guidance, suggest a positive outlook. The absence of negative surprises or unclear guidance supports a positive sentiment, likely resulting in a stock price increase of 2% to 8% over the next two weeks.
CERS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
